UniQure Pre-Tax Profit Margin 2013-2022 | QURE
UniQure pre-tax profit margin from 2013 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| UniQure Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2022-09-30 |
$0.06B |
$-0.13B |
-206.56% |
| 2022-06-30 |
$0.06B |
$-0.11B |
-183.87% |
| 2022-03-31 |
$0.53B |
$0.33B |
62.36% |
| 2021-12-31 |
$0.52B |
$0.33B |
63.74% |
| 2021-09-30 |
$0.50B |
$0.31B |
61.80% |
| 2021-06-30 |
$0.50B |
$0.29B |
58.20% |
| 2021-03-31 |
$0.04B |
$-0.16B |
-407.89% |
| 2020-12-31 |
$0.04B |
$-0.14B |
-373.68% |
| 2020-09-30 |
$0.01B |
$-0.17B |
-2371.43% |
| 2020-06-30 |
$0.01B |
$-0.14B |
-2266.67% |
| 2020-03-31 |
$0.01B |
$-0.12B |
-2066.67% |
| 2019-12-31 |
$0.01B |
$-0.12B |
-1771.43% |
| 2019-09-30 |
$0.01B |
$-0.11B |
-1750.00% |
| 2019-06-30 |
$0.01B |
$-0.10B |
-1287.50% |
| 2019-03-31 |
$0.01B |
$-0.09B |
-1022.22% |
| 2018-12-31 |
$0.01B |
$-0.08B |
-754.55% |
| 2018-09-30 |
$0.01B |
$-0.09B |
-733.33% |
| 2018-06-30 |
$0.01B |
$-0.08B |
-700.00% |
| 2018-03-31 |
$0.01B |
$-0.08B |
-600.00% |
| 2017-12-31 |
$0.01B |
$-0.08B |
-607.69% |
| 2017-09-30 |
$0.02B |
$-0.07B |
-347.37% |
| 2017-06-30 |
$0.02B |
$-0.07B |
-291.67% |
| 2017-03-31 |
$0.02B |
$-0.07B |
-304.35% |
| 2016-12-31 |
$0.02B |
$-0.07B |
-300.00% |
| 2016-09-30 |
$0.02B |
$-0.08B |
-405.26% |
| 2016-06-30 |
$0.02B |
$-0.09B |
-568.75% |
| 2016-03-31 |
$0.01B |
$-0.09B |
-650.00% |
| 2015-12-31 |
$0.01B |
$-0.08B |
-754.55% |
| 2015-09-30 |
$0.01B |
$-0.08B |
-877.78% |
| 2015-06-30 |
$0.01B |
$-0.06B |
-1033.33% |
| 2015-03-31 |
$0.01B |
$-0.05B |
-1060.00% |
| 2014-12-31 |
$0.01B |
$-0.05B |
-833.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.946B |
$0.106B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
